Sartorius Stedim Biotech Second Quarter 2025 Earnings: EPS Misses Expectations

Sartorius Stedim Biotech (EPA:DIM) Second Quarter 2025 Results

Key Financial Results

• Revenue: €745.0m (up 5.5% from 2Q 2024).
• Net income: €68.5m (up 44% from 2Q 2024).
• Profit margin: 9.2% (up from 6.7% in 2Q 2024). The increase in margin was driven by higher revenue.
• EPS: €0.69 (up from €0.50 in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sartorius Stedim Biotech EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.

Performance of the market in France.

The company's shares are down 11% from a week ago.

Risk Analysis

Be aware that Sartorius Stedim Biotech is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.